MedAdvisor Past Earnings Performance

Past criteria checks 0/6

MedAdvisor's earnings have been declining at an average annual rate of -5.4%, while the Healthcare Services industry saw earnings growing at 14.3% annually. Revenues have been growing at an average rate of 50.5% per year.

Key information

-5.4%

Earnings growth rate

14.8%

EPS growth rate

Healthcare Services Industry Growth42.6%
Revenue growth rate50.5%
Return on equity-16.2%
Net Margin-8.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Apr 24
Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Mar 20
Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Dec 15
Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Apr 20
Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Jun 29
MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09
Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11
Is MedAdvisor (ASX:MDR) A Risky Investment?

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08
Is MedAdvisor (ASX:MDR) Using Too Much Debt?

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10
MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18
What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18
What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22
Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Revenue & Expenses Breakdown
Beta

How MedAdvisor makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:MDR Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23109-950
30 Sep 23104-1040
30 Jun 2398-1130
31 Mar 2396-870
31 Dec 2293-570
30 Sep 2280-1150
30 Jun 2268-1730
31 Mar 2266-1630
31 Dec 2164-1430
30 Sep 2152-1430
30 Jun 2139-1430
31 Mar 2128-1340
31 Dec 2018-1260
30 Sep 2014-1160
30 Jun 2010-1060
31 Mar 209-950
31 Dec 199-940
30 Sep 199-850
30 Jun 198-850
31 Mar 198-750
31 Dec 187-750
30 Sep 187-650
30 Jun 187-440
31 Mar 186-440
31 Dec 176-440
30 Sep 175-440
30 Jun 174-330
31 Mar 173-420
31 Dec 162-420
30 Sep 162-410
30 Jun 161-310
31 Mar 161-210
31 Dec 152-110
30 Sep 152-110
30 Jun 152-100
30 Jun 141-100
30 Jun 131000

Quality Earnings: MDR is currently unprofitable.

Growing Profit Margin: MDR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MDR is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare MDR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (14.3%).


Return on Equity

High ROE: MDR has a negative Return on Equity (-16.19%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.